Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

B-cell malignancy indications: MCL and CLL/ SLL. With this submission, Pharmacyclics has also requested Priority Review. Pharmacyclics is jointly developing ibrutinib with Janssen.

Further information on the implications of this filing for potential commercialization will be provided subsequent to the FDA rendering a decision on the filing.

Corporate UpdateOver the past months Pharmacyclics has steadily advanced the build out of its Sales, Marketing and Medical Affairs Organizations. As of today, key executives for these areas and their respective staff have been hired and have been integrated into the Company. In addition, Pharmacyclics has hired a total of 62 Sales Representatives for its US territories and is currently on-boarding and training them to be ready in the event the FDA finalizes their review of the most recently filed New Drug Application and awards a label. Our partner Janssen already has an oncology sales organization in place. The Market Access, Marketing, Business Analytics & Informatics and Public Relations organizations have also been established. Together with Janssen, we now have a commercial team with a reach across all US regions that will be launch ready. This is not to be interpreted as an indication of when or if the FDA will provide us a label.

The Medical Affairs Group has also significantly grown, with four specific functional teams now established: Medical Sciences, Medical Communications, Medical Information, Medical Science Liaisons. Pharmacyclics has also hired seasoned professionals to support post-marketing safety activities. We have also bolstered our legal affairs team, now consisting of contracts, corporate compliance, intellectual property and corporate legal to protect and advance the corporate mission. Over the past 6 months Pharmacyclics hired a total of 220 employees, and has increased the total headcount to 415 employees as of the end of June.
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 2011 Reportlinker.com announces that a new market research ... Pain Therapeutics - Drugs, Markets and Companies ... report describes the latest concepts of pathomechanisms of pain ... pharmacotherapies for pain. Major segments of the pain market ...
... Pharmacotherapy research is set to become vastly more ... Wolters Kluwer Pharma Solutions , parent of the ... scientific information and analytics to professionals in the pharmaceutical and ... access (OA) publishing option for authors submitting original research articles ...
Cached Medicine Technology:Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 2Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 3Adis Journals Embrace Open Access 2Adis Journals Embrace Open Access 3Adis Journals Embrace Open Access 4
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
(Date:4/23/2014)... Using frozen stool from healthy, unrelated donors was ... relapsing diarrhea caused by Clostridium difficile , ... Clinical Infectious Diseases and available online. ... equally effective whether given via a colonoscope or ... may make this promising treatment more readily available ...
(Date:4/23/2014)... to give exercise enthusiasts the extra nudge they need ... a cyber buddy can help. , The study, which ... is the first to indicate that although a human ... software-generated partner also can be effective. , "We wanted ... motivate people to give greater effort while exercising than ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... be the cause, experts say , WEDNESDAY, May 26 (HealthDay ... older person,s condition. , The joint disease occurs over time ... allowing the bones to rub together and causing pain, swelling ... it,s like death and taxes -- you will likely get ...
... ... new member to its Board of Directors. The announcement was made by Jim Clarke, founder and ... ... a new member to its Board of Directors. The announcement was made by Jim Clarke, founder ...
... ... to health and beauty PR agency Robin Leedy & Associates (RL&A), helping to develop ... ... and beauty PR specialists Robin Leedy & Associates (RL&A) , a niche brand ...
... ... of their latest product Performance Canvas 2.2 as a mobile analytics ... 2.2 with Planning, the first fully unified Information Synthesis, Performance Management ... Sharepoint 2010 and SQL Analysis Services R2. The Performance Canvas Mobile ...
... ... are proud to team with the L.A. Dodger,s ThinkCure organization for "YAS-A-THON for ThinkCure," ... ... Fowler and her YAS Fitness Centers are proud to team with the L.A. Dodger,s ...
... ... Jones will take over as President of the company effective July 1st, 2010. , ... Waterloo, IA (Vocus) May 26, 2010 -- John Spragle ... retirement and VGM Insurance,s plan for my successor. Effective June 1, 2010, Tom Jones will be ...
Cached Medicine News:Health News:Osteoarthritis Claims Growing Number of Younger Victims 2Health News:Osteoarthritis Claims Growing Number of Younger Victims 3Health News:2 BigHearts Board Announces Addition to Board of Directors: Michael Unetich 2Health News:Robin Leedy & Associates Hires Digital Content Producer, Taking Social Media for Drugstore Brands Digital Capability to the Next Level 2Health News:Robin Leedy & Associates Hires Digital Content Producer, Taking Social Media for Drugstore Brands Digital Capability to the Next Level 3Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 3Health News:REBEL WITH A CAUSE: Kimberly Fowler and YAS Fitness Centers Roll with L.A. Dodgers to Cure Cancer 2Health News:REBEL WITH A CAUSE: Kimberly Fowler and YAS Fitness Centers Roll with L.A. Dodgers to Cure Cancer 3Health News:VGM Insurance President Passes the Baton 2
... The TC-PLUS Solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
... Proven Knee System is a long term, ... design. Available in both posterior stabilized and ... Knee System provides the flexibility needed to ... and ease of identification keeps the user ...
... FluoroNav Virtual Fluoroscopy software ... Technologies has incorporated ease ... technology features such as ... three-dimensional models of image ...
... T.L.I.F. SG Instruments are the next evolution ... comprehensive and functionally sound instruments.. The T.L.I.F. ... disc removal and disc preparation instruments designed ... Excellent design, a wide range of instrument ...
Medicine Products: